Carlsmed, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here is how Align Technology (ALGN) and Carlsmed, Inc. (CARL) have performed compared to their sector so far this year.
Carlsmed, Inc. (CARL) Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsMichael Cordonnier - Co-Founder,...
Presenter SpeechUnknown Analyst [Audio Gap] Can you just take the opportunity to go through maybe an introduction of the company and what are some key long-term growth drivers.Presenter
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
As you might know, Carlsmed, Inc. ( NASDAQ:CARL ) just kicked off its latest quarterly results with some very strong...
Carlsmed (NASDAQ:CARL) reported first-quarter 2026 revenue of $16.1 million, up 58% from $10.2 million in the prior-year period, as the company highlighted continued surgeon adoption of its patient-specific “aprevo” spine fusion procedures and ongoing efficiency gains in its digital production syste
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call May 5, 2026 4:30 PM EDTCompany ParticipantsStephanie ZhadkevichMichael Cordonnier - Co-Founder, Chairman, CEO...
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed First Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now...
Carlsmed, Inc. (CARL) delivered earnings and revenue surprises of +24.71% and +12.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Need a quote from a Motley Fool analyst? Joining me on today's call are Michael Cordonnier, chairman and chief executive officer, and Leonard Greenstein, chief financial officer. Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Carlsmed (CARL) smashed Q1 estimates with $16.1M revenue and raised 2026 guidance to $72M-$77M, driving shares up 4% after-market.
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD,...
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $70.000 million-$75.000 million to $72.000 million-$77.000 million vs $72.807 million estimate.
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. The company reported quarterly sales of $16.100 million which beat the analyst
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 --...
CARLSBAD, Calif., April 28, 2026 -- Carlsmed, Inc. , today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of...
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and lowers the price target from $20 to $18.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 113.7K | $1.03M | 0.00% | Added+64.9% | 2026-03-31 |
| RenTech | quant | 10.4K | $94.12K | 0.00% | Trimmed-57.2% | 2026-03-31 |
| FidelityFMR | fundamental | 1.3K | $11.73K | 0.00% | Added+322.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -0.39 | — | — |
| 2026-05-05 | -0.39 | -0.26 | +33.34% |
| 2026-02-25 | -0.43 | -0.29 | +31.54% |
| 2025-11-06 | -0.49 | -0.37 | +24.51% |
| 2025-08-28 | -0.91 | -1.37 | -49.32% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CARL | +20.46% | -13.55% | -7.53% | — |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +17.49% | -8.91% | -4.09% | — |